Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform
Novartis halted its mid-stage ALS drug trial for VHB937 but exercised a $125 million option to acquire Sironax's brain delivery platform.
Share
Why It Matters
Novartis stopped testing one medicine that didn't work out. But they bought a tool to deliver medicines into the brain.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.